		<u>'</u>			4						
	TD A NOM		• ,	Application Number		09/830,502					
E	TRANSMI FORI			Filing Date		October 29, 1999					
(C) (5)	(to be used for all correspond	_	al filing)	First Named Inventor		Barany et al.					
2003				Group Art Unit		1652					
4				Examiner Name		R. Hutson 19603/2615 (CRF D-2408)					
1.5.	Total Number of Pages in This S	ubmission		Attorney Docket Number							
F			ENCLOSUI	RES (check all that apply)							
区	Fee Transmittal Form			ent Papers		After Allowance Communication to Group					
.	Fee Attached			(pplication)		Appeal Communication to Board of					
	•		Drawing	•		Appeals and Interferences  Appeal Communication to Group					
	Amendment / Reply			ion and Power of Attorney	_	(Appeal Notice, Brief, Reply Brief)					
	After Final			g-related Papers		Proprietary Information Status Letter					
	☐ Affidavits/declaration(s)		Petition			Application Data Sheet					
×	Extension of Time Request		Applicat			Request for Corrected Filing Receipt with Enclosures					
	Express Abandonment Reque			f Attorney, Revocation of Correspondence Address	×	A self-addressed, prepaid postcard for acknowledging receipt					
	•	nent	Termina	l Disclaimer		Other Enclosure(s) (please identify below):					
ļ⊔	Certified Copy of Priority Document(s)		Request	for Refund	×	A copy of Notice to Comply					
	Response to Missing Parts/		CD, Nun	mber of CD(s)	×	Statement in Accordance with 37 C.F.R. § 1.821(g)					
	Incomplete Application				×	Sequence Listing (16 pages)					
	A copy of the Notice to M				×	Computer readable 3.5" diskette					
	under 37 CFR 1.52 or 1.5	3			×	containing sequences  Notification Regarding Loss of Entitlement to Small Entity Status Pursuant to 37 CFR §§ 1.27(g)(2) and 1.28(c)  ereby authorized to charge any additional fees					
RECE	ENED 9 5003 EOFPETITIONS		Remarks	The Commissioner is	hereb						
ع ا	COFPETITION			nts to Deposit Account No. 14-1138 for the							
OFFIC		SIGNATU	RE OF APPL	above identified docket nur ICANT, ATTORNEY, (		GENT &					
Firm or		Michael L. Nixon Peal Clinton Sq Rochester,	body LLP uare, P.O. Box 31051 New York 14603-1051 (585) 263-1304								
Sig	nature	Mu	hul	J. Jelle							
Dat	re	Soo	ember	2,2003	2, 2003						
	CFR	CIFICATE C	F MAILING	G OR TRANSMISSION	V 137	CFR 1.8(a)]					
I h	ereby certify that this corn				. [- /						
		velope addre				w with sufficient postage as first ioner for Patents, P. O. Box 1450,					
	transmitted by face $Q = \begin{pmatrix} 703 \\ 3 \\ 0 \\ 2 \end{pmatrix}$	simile on the	date shown	below to the United St	ates 1	Patent and Trademark Office at					
-	7/3/03 Date			_ were	101	onature /					
	Date			<u> </u>	len	printed name					
L				1 yp	OI	printed name					

# FOR FY 2003 Fint fees are subject to annual revision. att claims small entity status. See 37 CFR 1.27

OTAL AMOUNT OF PAYMENT (	\$) 315

	nplete if Known	
Application Number	09/830,502	Λ.
Filing Date	October 29, 1999 ·	MECA
First Named Inventor	Barany et al.	OF EIVER
Examiner Name	R. Hutson	SEP SO
Art Unit	1652	OFFICE 9 2002
Attorney Docket No.	19603/2615 (CRF D-2408)	CEOFP

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)								
Check Credit Card Money Order None	3. A	DDITIO							
Deposit Account:	Large Entity   Small Entity								
Deposit Account 14-1138	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description				
Number	1051	130	2051	65	Surcharge – late filing fee or oath				
	1052	50	2052	25	Surcharge - late provisional filing fee or cover				
Donosit C	1053	130	1053	130	sheet Non-English specification				
Deposit Account Nixon Peabody LLP	l		i		<u> </u>				
Name	1812	2,520	1812	2,520	For filing a request for ex parte reexamination				
The Commissioner is authorized to: (check all that apply)	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action				
Charge fee(s) indicated below Credit any overpayments	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner	-			
Charge any additional fee(s)	1251	110	2251	55	action Extension for reply within first month	110			
	l		1		_	110			
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.	1252	410	2252	205	Extension for reply within second month				
	1253	930	2253	465	Extension for reply within third month				
FEE CALCULATION	1254	1,450	2254	725	Extension for reply within fourth month				
1. BASIC FILING FEE	1255	1,970	2255	985	Extension for reply within fifth month				
Large Entity Small Entity Fee Fee Fee Fee Description	1401	320	2401	160	Notice of Appeal				
Code (\$) Code (\$) Fee Paid	1402	320	2402	160	Filing a brief in support of an appeal				
	1403	280	2403	140	Request for oral hearing				
1001 750 2001 375 Utility filing fee	1451	1,510	1451	1,510	Petition to institute a public use proceeding				
1002 330 2002 165 Design filing fee	1452	110	2452	55	Petition to revive – unavoidable				
1003 520 2003 260 Plant filing fee	1453	1,300	2453	650	Petition to revive – unintentional				
1004 750 2004 375 Reissue filing fee	1501	1,300	2501	650	Utility issue fee (or reissue)				
1005 160 2005 80 Provisional filing fee	1502	470	2502	235	Design issue fee				
	1503	630	2503	315	Plant issue fee				
SUBTOTAL (1) (\$) 0	1460	130	1460	130	Petitions to the Commissioner				
	1807	50	1807	50	Processing fee under 37 CFR 1.17(q)				
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1806	180	1806	180	Submission of Information Disclosure Stmt				
Fee from	8021	40	8021	40	Recording each patent assignment per property				
Total Claims below Fee Paid  Total Claims -20** = X = 0	1809	750	2809	375	(times number of properties) Filing a submission after final rejection				
					(37 CFR 1.129(a))				
Independent3** = X = _0	1810	750	2810	375	For each additional invention to be examined (37 CFR 1.129(b))				
Multiple Dependent X = 0	1801	750	2801	375	Request for Continued Examination (RCE)				
Large Entity Small Entity	1802	900	1802	900	Request for expedited examination of a design				
Fee Fee Fee <u>Fee Description</u>	1.002	,,,,	1802 900		application				
Code (\$) Code (\$)	Other	fee (speci	fy) Enti	y Deficienc	cy Payment	205			
1202 18 2202 9 Claims in excess of 20									
1201 84 2201 42 Independent claims in excess of 3	*Dad	oad by Da	eio Fili-	g Fee Paid	SUBTOTAL (3) (\$) 315				
1203 280 2203 140 Multiple dependent claim, if not paid	Redu	ced by Ba	SIC PHILI	g ree raid	SOBIOTAL (3) (3) 313				
1204 84 2204 42 ** Reissue independent claims over			FRTIF	ICATE OF	MAILING OR TRANSMISSION (37 CFR 1 8(a))				
original patent 1205 18 2205 9 ** Reissue claims in excess of 20 and	CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]  I hereby certify that this correspondence is being:								
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent		,		•	nited States Postal Service on the date shown below wi	th sufficient			
SUBTOTAL (2) (S) 0		po	stage as	first class r	mail in an envelope addressed to: Mail Stop Sequence				
**or number previously paid, if greater; For Reissues, see above					tents, P. O. Box 1450, Alexandria, VA 22313-1450				
				Office at (	nile on the date shown below to the United States Paten	a aiki			
		9/:	3/03		ullreduk. ble	ry			
		Date	e		11 o Signature 1 RA	Con			
	1				Typed or printed name	<u>~                                    </u>			
	<u> </u>				Typed of printed lame				
SUBMITTED BY					Complete (if applicable)				
Name (Print/Type) Michael L. Goldman	_	ration No ney/Agen		30,727	Telephone (585) 263-1304				
Signature J. J.		gen	·/		Date September	2,203			

Application No.: 10/830,502

Application No.: 10/830,502

POTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING

NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

		·
X	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2.	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5.	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6.	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X Ap		Applicants sequence listing submission lists discriptor <223> as a probe or primer for protein sequences. Protein sequences cannot be "probe or primer".  icant Must Provide:
X	Α	n initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
X		n initial_or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry to the specification.
X	а	statement that the content of the paper and computer readable copies are the same and, where pplicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 825(b) or 1.825(d).
Fo	· q	uestions regarding compliance to these requirements, please contact:
Fo	- F	Rules Interpretation, call (703) 308-4216

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE FNTERED

For CRF Submission Help, call (703) 308-4212 For Patentin software help, call (703) 308-6856

Nixon Peabody LLP

JUL 2 8 2003

August 3,2003



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Offic COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED	ATTORNEY DOCKET NO.		
		 			_
				EXAMINER	_
			ART UNIT	PAPER NUMBE	R
•		1	DATE MAII ED:	13	

PI ase find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth: As indicated on the attached Notice to Comply, the discriptor <223> cannot list "probe or primer" for protein sequences. See the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner Richard Hutson. Art Unit 1652, whose telephone number is (703) 308-0066.

Any inquiry of a general nature or relating to the status of this application should be directed to the Customer Service Center whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Richard Hutson, Ph.D. Primary Examiner Art Unit 1652 7/1/2003



## United States Patent and Trademark Office

CAMPED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.nspto.gov

DATE MAILED: 07/03/2003

FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. FILING DATE APPLICATION NO. 10/09/2001 19603/2615 8225 09/830,502 Francis Barany 7590 07/03/2003 Michael L Goldman **EXAMINER** Nixon Peabody HUTSON, RICHARD G Clinton Square P O Box 31051 Rochester, NY 14603 ART UNIT PAPER NUMBER 1652

Please find below and/or attached an Office communication concerning this application or proceeding.



RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/830,502A

DATE: 05/22/2003 TIME: 11:10:39

Input Set : A:\C26151.app

Output Set: N:\CRF4\05222003\I830502A.raw

```
attgaggaga ggacgggcaa ggacccaagg gccctcacgg cctag
                                                                       2025
202 <210> SEQ ID NO: 3
203 <211> LENGTH: 20
204 <212> TYPE: DNA
205 <213> ORGANISM: Artificial Sequence
207 <220> FEATURE:
208 <223> OTHER INFORMATION: Description of Artificial Sequence: probe or
209
          primer
211 <220> FEATURE:
212 <221> NAME/KEY: tRNA
213 <222> LOCATION: (4)
214 <223> OTHER INFORMATION: w at position 4 can be T or A
216 <220> FEATURE:
217 <221> NAME/KEY: unsure
218 <222> LOCATION: (5)
219 <223> OTHER INFORMATION: s at position 5 can be C or G
221 <220> FEATURE:
222 <221> NAME/KEY: unsure
223 <222> LOCATION: (12)
224 <223> OTHER INFORMATION: s at position 12 can be C or G
226 <220> FEATURE:
227 <221> NAME/KEY: unsure
228 <222> LOCATION: (15)
229 <223> OTHER INFORMATION: r at position 15 can be G or A
231 <220> FEATURE:
232 <221> NAME/KEY: unsure
233 <222> LOCATION: (18)
234 <223> OTHER INFORMATION: y at position 18 can be T or C
236 <400> SEQUENCE: 3
                                                                       20
237 atcwscgacg csgartayga
240 <210> SEQ ID NO: 4
241 <211> LENGTH: 7
242 <212> TYPE: PRT
243 <213> ORGANISM: Artificial Sequence
245 <220> FEATURE:
246 <223> OTHER INFORMATION: Description of Artificial Sequence: probe or
         primer
247
249 <400> SEQUENCE: 4
250 Ile Ser Asp Ala Glu Tyr Asp
251 1
254 <210> SEQ ID NO: 5
255 <211> LENGTH: 20
256 <212> TYPE: DNA
257 <213> ORGANISM: Artificial Sequence
259 <220> FEATURE:
260 <223> OTHER INFORMATION: Description of Artificial Sequence: probe or
         primer
261
263 <220> FEATURE:
264 <221> NAME/KEY: unsure
```

## RAW SEQUENCE LISTING DATE: 05/22/2003 PATENT APPLICATION: US/09/830,502A TIME: 11:10:39

Input Set : A:\C26151.app

Output Set: N:\CRF4\05222003\I830502A.raw

265 <222> LOCATION: (3) 266 <223> OTHER INFORMATION: s at position 3 can be C or G 268 <220> FEATURE: 269 <221> NAME/KEY: unsure 270 <222> LOCATION: (6) 271 <223> OTHER INFORMATION: s at position 6 can be C or G 273 <220> FEATURE: 274 <221> NAME/KEY: unsure 275 <222> LOCATION: (8) 276 <223> OTHER INFORMATION: k at position 8 can be G or T 278 <220> FEATURE: 279 <221> NAME/KEY: unsure 280 <222> LOCATION: (9) 281 <223> OTHER INFORMATION: s at position 9 can be G or C 283 <220> FEATURE: 284 <221> NAME/KEY: unsure 285 <222> LOCATION: (12) 286 <223> OTHER INFORMATION: s at position 12 can be G or C 288 <220> FEATURE: 289 <221> NAME/KEY: unsure 290 <222> LOCATION: (15) 291 <223> OTHER INFORMATION: y at position 15 can be C or T 293 <220> FEATURE: 294 <221> NAME/KEY: unsure 295 <222> LOCATION: (18) 296 <223> OTHER INFORMATION: r at position 18 can be A or G 298 <400> SEQUENCE: 5 20 299 ccsgtscksc csacytgraa 302 <210> SEQ ID NO: 6 303 <211> LENGTH: 20 304 <212> TYPE: DNA 305 <213> ORGANISM: Artificial Sequence 307 <220> FEATURE: 308 <223> OTHER INFORMATION: Description of Artificial Sequence: probe or 309 primer 311 <220> FEATURE: 312 <221> NAME/KEY: unsure 313 <222> LOCATION: (9) 314 <223> OTHER INFORMATION:  $\dot{v}$  at position 9 can be C, G, or A 316 <220> FEATURE: 317 <221> NAME/KEY: unsure 318 <222> LOCATION: (11) 319 <223> OTHER INFORMATION: r at position 11 can be A or G 321 <220> FEATURE: 322 <221> NAME/KEY: unsure 323 <222> LOCATION: (12) 324 <223> OTHER INFORMATION: y at position 12 can be T or C 326 <220> FEATURE:

327 <221> NAME/KEY: unsure

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 05/22/2003 PATENT APPLICATION: US/09/830,502A TIME: 11:10:40

Input Set : A:\C26151.app

Output Set: N:\CRF4\05222003\1830502A.raw

#### Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

```
Seq#:15; Xaa Pos. 18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36
Seq#:15; Xaa Pos. 37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55
Seq#:15; Xaa Pos. 56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74
Seq#:15; Xaa Pos. 75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93
Seq#:15; Xaa Pos. 94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109
Seq#:15; Xaa Pos. 110,111,112,113,114,115,116,117,118,119,120,126,127,128
Seq#:15; Xaa Pos. 129,130,131,132,133,134,135,136,137,138,139,140,141,142
Seq#:15; Xaa Pos. 143,144,145,146,147,148,149,150,151,152,153,154,155,156
Seq#:15; Xaa Pos. 157,158,159,160,161,162,163,164,165,166,167,168,169,170
Seq#:15; Xaa Pos. 171,172
Seq#:16; Xaa Pos. 18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36
Seq#:16; Xaa Pos. 37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55
Seq#:16; Xaa Pos. 56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74
Seq#:16; Xaa Pos. 75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93
Seq#:16; Xaa Pos. 94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109
Seq#:16; Xaa Pos. 110,111,112,113,114,115,116,117,118,119,120,129,130,131
Seq#:16; Xaa Pos. 132,133,134,135,136,137,138,139,140,141,142,143,144,145
Seq#:16; Xaa Pos. 146,147,148,149,150,151,152,153,154,155,156,157,158,159
Seq#:16; Xaa Pos. 160,161,162,163,164,165,166,167,168,169,170,171,172,173
Seg#:16; Xaa Pos. 174,175
Seq#:17; Xaa Pos. 18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36
Seq#:17; Xaa Pos. 37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55
Seq#:17; Xaa Pos. 56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74
Seq#:17; Xaa Pos. 75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93
Seq#:17; Xaa Pos. 94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109
Seq#:17; Xaa Pos. 110,111,112,113,114,115,116,117,118,119,120,126,127,128
Seq#:17; Xaa Pos. 129,130,131,132,133,134,135,136,137,138,139,140,141,142
Seq#:17; Xaa Pos. 143,144,145,146,147,148,149,150,151,152,153,154,155,156
Seq#:17; Xaa Pos. 157,158,159,160,161,162,163,164,165,166,167,168,169,170
Seq#:17; Xaa Pos. 171,172
Seq#:18; Xaa Pos. 18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36
Seq#:18; Xaa Pos. 37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55
Seq#:18; Xaa Pos. 56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74
Seq#:18; Xaa Pos. 75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93
Seq#:18; Xaa Pos. 94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109
Seq#:18; Xaa Pos. 110,111,112,113,114,115,116,117,118,119,120,126,127,128
Seq#:18; Xaa Pos. 129,130,131,132,133,134,135,136,137,138,139,140,141,142
Seq#:18; Xaa Pos. 143,144,145,146,147,148,149,150,151,152,153,154,155,156
Seq#:18; Xaa Pos. 157,158,159,160,161,162,163,164,165,166,167,168,169,170
Seq#:18; Xaa Pos. 171,172
Seq#:19; Xaa Pos. 18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36
Seq#:19; Xaa Pos. 37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55
Seq#:19; Xaa Pos. 56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74
Seq#:19; Xaa Pos. 75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93
```

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 05/22/2003 PATENT APPLICATION: US/09/830,502A TIME: 11:10:40

Input Set : A:\C26151.app

Output Set: N:\CRF4\05222003\I830502A.raw

Seq#:19; Xaa Pos. 94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109
Seq#:19; Xaa Pos. 110,111,112,113,114,115,116,117,118,119,120,126,127,128
Seq#:19; Xaa Pos. 129,130,131,132,133,134,135,136,137,138,139,140,141,142
Seq#:19; Xaa Pos. 143,144,145,146,147,148,149,150,151,152,153,154,155,156
Seq#:19; Xaa Pos. 157,158,159,160,161,162,163,164,165,166,167,168,169,170
Seq#:19; Xaa Pos. 171,172
Seq#:20; Xaa Pos. 18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36

VERIFICATION SUMMARY

DATE: 05/22/2003

PATENT APPLICATION: US/09/830,502A

TIME: 11:10:40

Input Set : A:\C26151.app

Output Set: N:\CRF4\05222003\1830502A.raw

L:470 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15 after pos.:16 M:341 Repeated in SeqNo=15 L:523 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16 after pos.:16 M:341 Repeated in SeqNo=16 L:576 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17 after pos.:16 M:341 Repeated in SeqNo=17 L:629 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18 after pos.:16 M:341 Repeated in SeqNo=18 L:682 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19 after pos.:16 M:341 Repeated in SeqNo=19 L:735 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20 after pos.:16 M:341 Repeated in SeqNo=20

سور کا کا کا

STATISTICS SUMMARY

PATENT APPLICATION: US/10/085,418E

DATE: 05/22/2003 TIME: 14:24:44

Input Set : N:\jumbos\10085418\PTOMS.txt Output Set: N:\CRF4\05222003\J085418E.raw

Application Serial Number: US/10/085,418E

Alpha or Numeric or Xml: Alpha

Application Class:

Application File Date: 02-28-2002

Art Unit: OIPE

Software Application: PatentIN1.0

Total Number of Sequences: 3

Total Nucleotides: 3729

Total Amino Acids: 0 Number of Errors: 0

Number of Warnings: 0

Number of Corrections: 2

### MESSAGE SUMMARY

220 C: 2 (Keyword misspelled or invalid format)

e led 1 6 | 17 | 03

Does Not Comply
Corrected Diskette Needed



1600

RAW SEQUENCE LISTING DATE: 05/22/2003 PATENT APPLICATION: US/09/830,502A TIME: 11:10:39

Input Set : A:\C26151.app

Output Set: N:\CRF4\05222003\I830502A.raw

```
3 <110> APPLICANT: Barany, Francis
        Cao, Weiguo
        Tong, Jie
7 <120> TITLE OF INVENTION: HIGH FIDELITY THERMOSTABLE LIGASE AND USES THEREOF
9 <130> FILE REFERENCE: 19603/2615
11 <140> CURRENT APPLICATION NUMBER: 09/830,502A
12 <141> CURRENT FILING DATE: 1999-10-29
14 <150> PRIOR APPLICATION NUMBER: 60/106,461
15 <151> PRIOR FILING DATE: 1998-10-30
17 <150> PRIOR APPLICATION NUMBER: PCT/US99/25437
18 <151> PRIOR FILING DATE: 1999-10-29
20 <160> NUMBER OF SEQ ID NOS: 20
22 <170> SOFTWARE: PatentIn Ver. 2.1
24 <210> SEQ ID NO: 1
25 <211> LENGTH: 674
26 <212> TYPE: PRT
27 <213> ORGANISM: Thermus sp.
29 <400> SEQUENCE: 1
30 Met Thr Leu Glu Glu Ala Arg Arg Arg Val Asn Glu Leu Arg Asp Leu
                                                            15
                                       10
33 Ile Arg Tyr His Asn Tyr Leu Tyr Tyr Val Leu Asp Ala Pro Glu Ile
               20
36 Ser Asp Ala Glu Tyr Asp Arg Leu Leu Arg Glu Leu Lys Glu Leu Glu
                                40
39 Glu Arg Phe Pro Glu Leu Lys Ser Pro Asp Ser Pro Thr Glu Gln Val
                           55
42 Gly Ala Arg Pro Leu Glu Ala Thr Phe Arg Pro Val Arg His Pro Thr
                                           75
                        70
43 65
45 Arg Met Tyr Ser Leu Asp Asn Ala Phe Ser Leu Asp Glu Val Arg Ala
                                        90
                    85
48 Phe Glu Glu Arg Ile Glu Arg Ala Leu Gly Arg Lys Gly Pro Phe Leu
                                   105
               100
51 Tyr Thr Val Glu Arg Lys Val Asp Gly Leu Ser Val Asn Leu Tyr Tyr
                               120
54 Glu Glu Gly Ile Leu Val Phe Gly Ala Thr Arg Gly Asp Gly Glu Thr
                           135
                                               140
       130
57 Gly Glu Glu Val Thr Gln Asn Leu Leu Thr Ile Pro Thr Ile Pro Arg
                                           155
                       150
60 Arg Leu Thr Gly Val Pro Asp Arg Leu Glu Val Arg Gly Glu Val Tyr
                                       170
                   165
63 Met Pro Ile Glu Ala Phe Leu Arg Leu Asn Gln Glu Leu Glu Glu Ala
                                   185
               180
66 Gly Glu Arg Ile Phe Lys Asn Pro Arg Asn Ala Ala Ala Gly Ser Leu
```

RAW SEQUENCE LISTING

DATE: 05/22/2003 TIME: 11:10:39

PATENT APPLICATION: US/09/830,502A

Input Set : A:\C26151.app
Output Set: N:\CRF4\05222003\I830502A.raw

67			195					200					205			
69	Arq	Gln		Asp	Pro	Arg	Val		Ala	Arg	Arg	Gly	Leu	Arg	Ala	Thr
70	_	210					215					220				
72	Phe	Tyr	Ala	Leu	Gly	Leu	Gly	Leu	Glu	Glu	Thr	Gly	Leu	Lys	Ser	Gln
73	225					230					235					240
75	His	Asp	Leu	Leu	Leu	Trp	Leu	Arg	Glu		Gly	Phe	Pro	Val	Glu	His
76					245			_		250		~ 1	-1		255	<b>6</b> 3
	Gly	Phe	Thr		Ala	Leu	Gly	Ala		Gly	Val	Glu	GLu		Tyr	GIn
79		_		260		_	_		265	D	D1	C1	ת ז ה	270	C1	17-1
	Ala	Trp		Lys	GLu	Arg	Arg		Leu	Pro	Pne	GIU	285	ASP	СТУ	vaı
82	1	** - 1	275	T	7	7	T 0	280	T 011	Trn	Λκα	Glu		Gl v	Tur	Thr
	Val		ьуs	ьeu	Asp	Asp	ьеи 295	Ala	теп	тъ	ALG	300	пеи	GIY	ıyı	
85	71.	290	mb∽	Dro	7~~	Phe		Len	Δla	Tur	T.vs		Pro	Ala	Glu	Glu
	305	Arg	IIII.	FIO	Arg	310	ALA.	пеп	AIG	* Y * .	315	1110	120	1114	020	320
00	303 Tuc	Glu	Thr	Δra	T.e.11	Leu	Ser	Val	Ala	Phe		Val	Glv	Ara	Thr	
91	туз	OLU	1111	111 9	325	Dou	001			330			- 4	,	335	
93	Ara	Tle	Thr	Pro		Gly	Val	Leu	Glu		Val	Phe	Ile	Glu	Gly	Ser
94	9			340		1			345					350	_	
96	Glu	Val	Ser	Arg	Val	Thr	Leu	His	Asn	Glu	Ser	Phe	Ile	Glu	Glu	Leu
97			355					360					365			
99	Asp	Val	Arg	Ile	Gly	Asp	Trp	Val	Leu	Val	His	Lys	Ala	Gly	Gly	Val
100	)	370	)				375	5				380	)			
102	2 Ile	e Pro	Glu	ı Val	. Let	ı Arç	y Val	Leu	ı Lys	s Glu			Thi	c Gly	/ Glu	Glu
	385					390				_	395		~ .			400
		s Pro	) Ile	e Ile			Glu	ı Asr	n Cys			ı Cys	GI3	y His		a Leu
106	5	_		_,	405			_	<b>~</b>	410		. D			415	
		e Lys	s Glu			s val	. H15	s Arg			) ASI	1 PIC	) те	430	) PI(	) Ala
109			n Dha	420		. т1-	. n	~ uic	425		. Sar	- Arc	r T.37			Asp
		s Arc	g Pne 435		I Alc	1 116	e Arc	440		, AT	3 361	. ALG	, Буз 445		110	- ASP
112	<u>.</u> 1 Tl	- G1r			. G1s	, Gli	1 T.V.			- Glı	ı Lvs	Leu			ı Lvs	s Gly
115		450		, пес	. 01)	y Olt	455		`			460				<b>1</b>
111	7 T.e.i	ı Va	) I Arc	ı Asr	. Val	Ala			ı Tvı	r Arc	ı Lei	ı Lys	Lys	s Glu	ı Ası	Leu
	3 465			,		470			-		475		_		-	480
120	) Va.	l Ası	ı Lei	ı Glu	ı Arc	g Met	: Gly	y Glu	ı Lys	s Sea	r Ala	a Glu	ı Ası	n Lei	ي Le	Arg د
12:	L				485	5				490	)				49	5
123	3 Glı	n Ile	e Glu	ı Glu	ı Sei	Lys	Gly	y Arc	g Gly	y Lei	ı Glu	ı Arç	J Leι	u Let	ג Ty:	r Ala
124	4			500	)		٠,		50	5				510	)	
126	6 Le	ı Gl	y Lei	ı Pro	Ġly	y Val	Gly	y Glu	ı Va.	l Lei	ı Ala	a Arç	g Ası	n Lei	ı Ala	a Leu
12	7		515					520					52			
129	9 Ar	g Phe	e Gly	/ His	s Met	. Asp			ı Leı	ي Glı	Ala د			u Glı	ו Asן	o Leu
130	0	530				_	535		_			540		- 1		-
			ı Val	l Glu	ı Gly			y Glı	Le۱ د	a Th			g Ala	a IIe	e Le	u Asn
133	3 54	5			_	550		_	_	-	555		70	T	. т	560
		r Le	a Lys	s Asp			ı Phe	e Ar	g Ası			LAr	y Ar	a те	а Бу: 57	s Glu
130	b	~ 3			565		. 70 7	_ T	~ (-1)	570		, cı.	, Cl.	n 7\1	_	
		a GI	y va.			L GI	ı Ale	я гуу	58!		الدى و	ı GIŞ	, GT	u A16		u Lys
139	7			580	,				50.	,				55	•	

RAW SEQUENCE LISTING DATE: 05/22/2003 PATENT APPLICATION: US/09/830,502A TIME: 11:10:39

Input Set : A:\C26151.app

Output Set: N:\CRF4\05222003\I830502A.raw

```
141 Gly Leu Thr Phe Val Ile Thr Gly Glu Leu Ser Arg Pro Arg Glu Glu
                               600
                                                   605
            595
142
144 Val Lys Ala Leu Leu Arg Arg Leu Gly Ala Lys Val Thr Asp Ser Val
                                               620
                           615
145
        610
147 Ser Arg Lys Thr Ser Phe Leu Val Val Gly Glu Asn Pro Gly Ser Lys
                                           635
                        630
148 625
150 Leu Glu Lys Ala Arg Ala Leu Gly Val Pro Thr Leu Ser Glu Glu Glu
                    645
151
153 Leu Tyr Arg Leu Ile Glu Glu Arg Thr Gly Lys Asp Pro Arg Ala Leu
                                   665
                660
154
156 Thr Ala
160 <210> SEQ ID NO: 2
161 <211> LENGTH: 2025
162 <212> TYPE: DNA
163 <213> ORGANISM: Thermus sp.
165 <400> SEQUENCE: 2
166 atgaccotag aggaggcccg caggcgcgtc aacgaactca gggacctgat ccgttaccac 60
167 aactacetet attacgtett ggacgeecee gagateteeg aegeegagta egaceggete 120
168 cttagggagc ttaaggagct ggaggagcgc tttcccgagc tcaaaagccc cgactccccc 180
170 cgcatgtact ccctggacaa cgccttttcc ttggacgagg tgagggcctt tgaggagcgc 300
171 atagageggg ecetggggeg gaaggggeee tteetetaea eegtggageg eaaggtggae 360
172 ggtctttccg tgaacctcta ctacgaggag ggcatcctcg tctttggggc cacccggggc 420
173 gacggggaga ccggggagga ggtgacccag aacctcctca ccatccccac cattccccgc 480
174 cgcctcacgg gcgttccgga ccgcctcgag gtccggggcg aggtctacat gcccatagag 540
175 gccttcctca ggctcaacca ggagctggag gaggcggggg agcgcatctt caaaaacccc 600
176 aggaacgccg ccgccgggtc cttgcggcag aaagacccca gggtcacggc caggcggggc 660
177 ctgagggcca ccttttacgc cctggggctg ggcctggagg aaaccgggtt aaaaagccag 720
178 cacgacette tectatgget aagagagegg ggettteeeg tggageaegg etttaeeegg 780
179 gccctggggg cggaggggt ggaggaggtc taccaggcct ggctcaagga gaggcggaag 840
180 cttccctttg aggccgacgg ggtggtggtc aagctggacg acctcgccct ctggcgggag 900
181 ctggggtaca ccgcccgcac cccccgcttc gccctcgcct acaagttccc ggccgaggag 960
182 aaggagaccc gcctcctctc cgtggccttc caggtggggc ggaccgggcg catcaccccc 1020
183 gtgggcgttc tggagcccgt cttcatagag ggcagcgagg tgagccgggt caccctccac 1080
184 aacgagaget teattgagga getggaegtg egeateggeg aetgggtget ggteeacaag 1140
185 gcgggcgggg tgattcccga ggtgctgagg gtcctgaaag agcgccgcac cggggaggag 1200
186 aagcccatca tctggcccga gaactgcccc gagtgcggcc acgccctcat caaggagggg 1260
187 aaggtccacc gctgccccaa ccccttgtgc cccgccaagc gctttgaggc catccgccac 1320
188 tacgcctccc gcaaggccat ggacatccag ggcctggggg agaagctcat agaaaagctt 1380
189 ctggaaaagg gcctggtccg ggacgtggcc gacctctacc gcctgaagaa ggaggacctg 1440
190 gtgaacctgg agcgcatggg ggagaagagc gcagagaacc tcctccgcca gatagaggag 1500
191 agcaagggcc gcggcctgga gcgcctcctt tacgccctgg gccttcccgg ggtgggggag 1560
192 gtgctggccc ggaacctggc cctccgcttc ggccacatgg accgccttct ggaggcgggc 1620
193 ctcgaggacc tcctggaggt ggaggggtg ggcgagctca ccgcccgggc catcctgaat 1680
194 accetaaagg acceggagtt cegggacetg gtgcgccgcc tgaaggaggc eggggtggag 1740
195 atggaggcca aagagcggga gggcgaggcc ttgaaggggc tcaccttcgt catcaccggg 1800
196 gagettteec ggeeceggga ggaggtgaag geecteetta ggeggettgg ggeeaaggtg 1860
197 acggactcgg tgagccgcaa gacgagcttc ctggtggtgg gggagaaccc ggggagcaag 1920
198 ctggaaaagg cccgcgcctt gggggtcccc accctgagcg aggaggagct ctaccgcctc 1980
```